<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> respond to initial intense therapies, such as hyper-CVAD (hyperfractionated <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>/<z:chebi fb="0" ids="28445">vincristine</z:chebi>/<z:chebi fb="0" ids="28748">doxorubicin</z:chebi>/<z:chebi fb="0" ids="41879">dexamethasone</z:chebi>) alternating with high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi>/<z:chebi fb="0" ids="28680">cytarabine</z:chebi>, to which the monoclonal antibody rituximab has recently been added </plain></SENT>
<SENT sid="1" pm="."><plain>This report provides an update detailing the long-term outcome when this chemoimmunotherapy regimen is used as first-line therapy for newly diagnosed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>, de novo Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, atypical Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and mature B-cell <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Ninety-seven patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> and 31 patients with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, atypical Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> were treated with rituximab plus hyper-CVAD alternating with rituximab/<z:chebi fb="0" ids="44185">methotrexate</z:chebi>/<z:chebi fb="0" ids="28680">cytarabine</z:chebi> under different institutional trials approved by the University of Texas M </plain></SENT>
<SENT sid="3" pm="."><plain>D </plain></SENT>
<SENT sid="4" pm="."><plain>Anderson <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Center Institutional Review Board </plain></SENT>
<SENT sid="5" pm="."><plain>Overall response rate (RR) for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> was 97% (complete response [CR]/unconfirmed CR rate, 87%) </plain></SENT>
<SENT sid="6" pm="."><plain>At a median follow-up of 4.8 months, the 5-year failure-free survival and OS rates were 48% and 65%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Among patients aged &lt; or = 65 years, the 5 year failure-free survival was 60% </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with blastoid <z:mp ids='MP_0000002'>morphology</z:mp> have a 7-year survival rate of 47% </plain></SENT>
<SENT sid="9" pm="."><plain>Toxicity was mainly hematologic but significant </plain></SENT>
<SENT sid="10" pm="."><plain>Overall RR for patients with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/atypical Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> was 97% (CR rate, 86%) </plain></SENT>
<SENT sid="11" pm="."><plain>With a median follow-up of 22 months, the estimated 3-year OS, disease-free survival, and event-free survival rates were 89%, 88%, and 80%, respectively </plain></SENT>
<SENT sid="12" pm="."><plain>Rituximab plus hyper-CVAD alternating with rituximab/<z:chebi fb="0" ids="44185">methotrexate</z:chebi>/<z:chebi fb="0" ids="28680">cytarabine</z:chebi> is an effective dose-intense chemoimmunotherapy program for untreated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>, Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, atypical Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Toxicity is mainly hematologic and significant, but expected </plain></SENT>
</text></document>